New! Bruker Daltonics Provides Next-Generation Biopharmaceutical Characterization Solutions to Leading Pharma and Biotech Partners
Bruker introduces the first software solution to encompass the complete biopharmaceutical characterization challenge, including glycoforms, impurities and modifications.
Characterization Solutions to Leading Pharma and Biotech PartnersBruker introduces the first software solution to encompass the complete biopharmaceutical characterization challenge, including glycoforms, impurities and modifications. The unique BioPharmaCompass 1.1 software allows biotech customers to leverage Bruker’s leadership in cutting-edge mass spectrometry for intact protein and post-translational modification analysis in a routine industrial biologics environment. You will find several major enabling innovations in the quest for a complete picture of biological products for regulatory approval and compliance in BioPharma Compass 1.1 such as:
- Intact precise-mass product confirmation and impurity identification in a single run
- Handling of multiple-point time-course studies, impurity analysis against an expected batch standard, antibody-drug conjugate analysis, and stress studies
- Antibody determination by top-down sequencing with instant visualization of N and C terminal modification analysis
- Glycan profiling, PTM and artifact determination, localization and quantification including novel ETD (electron transfer dissociation) strategy for determination of deamidation sites
- Rapid identity testing by peptide mass fingerprinting
- Automatic combination of data from multiple enzymatic approaches for 100% sequence coverage even including formerly difficult-to-sequence domains
Bruker has pioneered the field of novel mass spectrometry techniques for the direct measurement and sequencing of intact proteins. The industry-leading highest resolution maXis ESI-QqTOF spectra available at maximum sensitivity for trace impurities, patented top-down ISD-T3 sequencing on Flex series MALDI TOF/TOF and best-in-class amazon ETD ion-trap technology for PTM analysis are all critical steps in a complete understanding of the composition of a biotherapeutic. Now, BioPharmaCompass 1.1 enables biotech and pharma customers to manage information from any or all of these unique capabilities, dramatically speeding the licensing and production of biological drugs.
For more information on BioPharmaCompass 1.1, please go to:
ref=http://www.bdal.com>www.bdal.com
